MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.drugalcdep.2017.01.026

Медицинская библиотека · Drug and alcohol dependence · 2017

Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.

Springer Sandra A, Di Paola Angela, Azar Marwan M, Barbour Russell, Krishnan Archana, Altice Frederick L

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Alcohol use disorders (AUDs) are highly prevalent among persons living with HIV (PLH) within the criminal justice system (CJS). Extended-release naltrexone (XR-NTX) has not been previously evaluated among CJS-involved PLH with AUDs.

METHODS

A randomized, double-blind, placebo-controlled trial was conducted among 100 HIV+ prisoners with AUDs. Participants were randomized 2:1 to receive 6 monthly injections of XR-NTX or placebo starting one week prior to release. Using multiple imputation strategies for data missing completely at random, data were analyzed for the 6-month post-incarceration period. Main outcomes included: time to first heavy drinking day; number of standardized drinks/drinking day; percent of heavy drinking days; pre- to post-incarceration change in average drinks/day; total number of drinking days; and a composite alcohol improvement score comprised of all 5 parameters.

RESULTS

There was no statistically significant difference overall between treatment arms for time-to-heavy-drinking day. However, participants aged 20-29 years who received XR-NTX had a longer time to first heavy drinking day compared to the placebo group (24.1 vs. 9.5days; p<0.001). There were no statistically significant differences between groups for other individual drinking outcomes. A sub-analysis, however, found participants who received ≥4 XR-NTX were more likely (p<0.005) to have improved composite alcohol scores than the placebo group. Post-hoc power analysis revealed that despite the study being powered for HIV outcomes, sufficient power (0.94) was available to distinguish the observed differences.

CONCLUSIONS

Among CJS-involved PLH with AUDs transitioning to the community, XR-NTX lengthens the time to heavy drinking day for younger persons; reduces alcohol consumption when using a composite alcohol consumption score; and is not associated with any serious adverse events.

Для цитирования: Springer Sandra A, Di Paola Angela, Azar Marwan M, Barbour Russell, Krishnan Archana, Altice Frederick L. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.. Drug and alcohol dependence. 2017. DOI: 10.1016/j.drugalcdep.2017.01.026.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.